



Fondazione  
Epatocentro Ticino

Università  
della  
Svizzera  
italiana

Institute for  
Research in  
Biomedicine



**3rd Swiss Autoimmune Liver Disease Meeting, March 13<sup>th</sup>-14<sup>th</sup> 2020**  
**Università della Svizzera Italiana, Auditorium**  
**Lugano, Switzerland**

**March 13<sup>th</sup>**

**Basic science session 1**

**Chairs: Andreas Cerny and Federica Sallusto**

- 11:00-11:10 Welcome and Introduction  
Andreas Cerny, Benedetta Terziroli Beretta-Piccoli
- 11:10-11:20 Welcome by Mario Bianchetti, founding Dean of the Master Medical School
- 11:20-11:40 Genetics in primary biliary cholangitis beyond GWAS  
Pietro Invernizzi, Italy
- 11:40-11:50 Discussion
- 11:50-12:10 Preventing the progression of PBC  
Eric Gershwin, USA
- 12:10-12:20 Discussion
- 12:20-12:40 Effector and regulatory T-cells in autoimmune diseases  
Federica Sallusto, Switzerland
- 12:40-12:50 Discussion
- 12:50-14:00 Lunch and poster viewing**

**Basic science session 2**

**Chairs: Michael Manns and Pietro Majno**

- 14:00-14:20 The impact of gut microbiome on T-cell trafficking  
Giandomenica Iezzi, Switzerland
- 14:20-14:30 Discussion
- 14:30-14:50 Novel approaches to autoantibody characterization



Fondazione  
Epatocentro Ticino

Università  
della  
Svizzera  
italiana

Institute for  
Research in  
Biomedicine



- Antonio Lanzavecchia, Switzerland
- 14:50-15:00 Discussion
- 15:00-15:20 Post-transplant autoimmune liver diseases  
Diego Vergani, UK
- 15:20-15:30 Discussion
- 15:30-15:50 The hepatic unique tolerogenic microenvironment  
Mala Maini, UK
- 15:50-16:00 Discussion
- 16:00-16:20 Coffee break
- 16:20-16:40 Anti-tumour autologous T-cell therapy for HBV-associated hepatocellular carcinoma  
Antonio Bertoletti, Singapore
- 16:40-16:50 Discussion
- 16:50-17:10 Animal model of autoimmune liver diseases  
Urs Christen, Germany
- 17:10-17:20 Discussion
- 17:20-17:40 Gut-liver axis  
Antonio Moschetta, Italy
- 17:40-17:50 Discussion
- 17:50-18:30 Oral presentations selected among submitted abstracts
1. TBC
  2. TBC
  3. TBC
- 18:30-18:40 What have we learned and what should we do next  
Michael Trauner, Austria

## **March 14<sup>th</sup>**

### **Clinical session 1**

**Chairs: Andrea De Gottardi and Maria Isabel Lucena**

- 8:30-8:50 Bile duct lesions in autoimmune hepatitis and interface hepatitis in primary biliary cholangitis  
Alberto Quaglia, UK
- 8:50-9:00 Discussion



Fondazione  
Epatocentro Ticino

Università  
della  
Svizzera  
italiana

Institute for  
Research in  
Biomedicine



- 9:00-09:20 Autoimmune hepatitis type 2  
Giorgina Mieli-Vergani, UK
- 9:20-09:30 Discussion
- 09:30-09:50 Imaging in sclerosing cholangitis  
Tom Hemming Karlsen, Norway
- 09:50-10:00 Discussion
- 10:00-10:20 Coffee break
- 10:20-10:40 There is more than one cause for primary sclerosing cholangitis  
Richard Thompson, UK
- 10:40-10:50 Discussion
- 10:50-11:10 Autoantibodies in autoimmune liver diseases: clinical aspects  
Luigi Muratori, Italy
- 11:10-11:20 Discussion
- 11:20-11:40 Beyond guidelines  
Michael Manns, Germany
- 11:40-11:50 Discussion
- 11:50-13:00 Lunch and poster viewing

## **Clinical session 2**

**Chairs: Eric Gershwin and Florian Bihl**

- 13:00-13:20 Drug-induced liver injury and autoimmunity  
Raul Andrade, Spain
- 13:20-13:30 Discussion
- 13:30-13:50 Immunometabolic drugs  
Michael Trauner, Austria
- 13:50-14:00 Discussion
- 14:00-14:45 Oral presentations selected among submitted abstracts
1. TBC
  2. TBC
  3. TBC
- 14:45-15:00 What have we learned and what should we do next  
Eric Gershwin, USA



Fondazione  
Epatocentro Ticino

Università  
della  
Svizzera  
italiana

Institute for  
Research in  
Biomedicine



15:00-15:10 Concluding remarks  
Andreas Cerny, Benedetta Terziroli